Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.57 |
| ▸ | BACE1 | P56817 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148664 | 1.00 | MAOB (0.60) | MAOBLCKGSK3BBACE1RAB9A | |
| SCHEMBL20024692 | 0.84 | LCK (0.77) | MAOBLCKGSK3BBACE1RAB9A | |
| SCHEMBL14786203 | 0.84 | LCK (0.77) | MAOBLCKGSK3BBACE1RAB9A | |
| SCHEMBL8913578 | 0.83 | LCK (0.81) | MAOBLCKGSK3BBACE1RAB9A | |
| SCHEMBL8913590 | 0.83 | LCK (0.81) | MAOBLCKGSK3BBACE1RAB9A | |
| SCHEMBL7006802 | 0.80 | KDM4E (0.56) | MAOBGSK3BBACE1RAB9ANPC1 | |
| SCHEMBL7006805 | 0.80 | KDM4E (0.56) | MAOBGSK3BBACE1RAB9ANPC1 | |
| SCHEMBL38650740 | 0.80 | LCK (0.66) | MAOBLCKGSK3BBACE1RAB9A | |
| SCHEMBL2092418 | 0.78 | LCK (0.64) | MAOBLCKGSK3BBACE1RAB9A | |
| SCHEMBL11896472 | 0.78 | LCK (0.64) | MAOBLCKGSK3BBACE1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567503-B1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-12-21 | — | — | EP | disclosed |
| CN-100482647-C | Pyrazole derivatives useful as COX-I inhibitors | ASTELLAS PHARMACY CO LTD (JP) | 2009-04-29 | — | — | CN | disclosed |
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| CN-1717393-A | Pyrazole derivatives as COX-1 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2006-01-04 | — | — | CN | disclosed |
| EP-1567503-A1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20040116475-A1 | Pyrazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| WO-2004050632-A1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | WO | disclosed |
| US-5721240-A | PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 1998-02-24 | — | — | US | disclosed |
| US-5565463-A | PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0460116-A4 | 9-SUBSTITUTED-8-UNSUBSTITUTED-9-DEAZAGUANINES | — | 1992-05-13 | — | — | EP | disclosed |
| EP-0460116-A1 | 9-SUBSTITUTED-8-UNSUBSTITUTED-9-DEAZAGUANINES. | BIOCRYST (US) | 1991-12-11 | — | — | EP | disclosed |
| WO-1990010631-A1 | 9-SUBSTITUTED-8-UNSUBSTITUTED-9-DEAZAGUANINES | BIOCRYST (US) | 1990-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | MAOB 601/4885LCK 2292/4885GSK3B 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.